Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.55 |
| ▸ | PPARG | P37231 | 10/20 | 0.55 |
| ▸ | PPARD | Q03181 | 5/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | SRR | Q9GZT4 | 4/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941128 | 0.98 | PPARA (0.56) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL4451311 | 0.98 | PPARA (0.56) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL3466702 | 0.98 | PPARA (0.56) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL5607495 | 0.96 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL5607756 | 0.96 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL5607096 | 0.96 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL5606722 | 0.96 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| Rubidium SCHEMBL5607497 | 0.96 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| SCHEMBL4811729 | 0.96 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR | |
| Ammonia Solution, Strong SCHEMBL5606748 | 0.96 | PPARA (0.55) | PPARAPPARGPPARDSLC7A5SRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1687250-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | Takasago International Corporation (JP) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051882-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | ALDH1A2, ALDH1A3, GRHPR | PPARA 472/4885PPARG 1052/4885PPARD 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.